Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers (NCT01416805) | Clinical Trial Compass
CompletedPhase 3
Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers
United States100 participantsStarted 2011-08
Plain-language summary
This study will examine the efficacy of a computerized cognitive behavioral therapy (CCBT) program for children with anxiety disorders in community health centers. The first phase of the study will offer insight into the feasibility of providing this intervention in community health centers, while the second phase will compare CCBT to treatment as usual.
Who can participate
Age range7 Years – 13 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Outpatient boys and girls with an anxiety disorder (see below) aged 7-13 years.
* Meets DSM-IV criteria for a diagnosis of one of the following anxiety disorders: separation anxiety disorder (SAD), generalized anxiety disorder (GAD), or social phobia.
* Minimum score of 14 on the PARS Severity Scale.
* The child has a Full Scale IQ greater than 80 as assessed on the Wechsler Abbreviated Scale of Intelligence.
* Have home access to a computer with internet connection.
Exclusion Criteria:
* Receiving concurrent psychotherapy or other counseling services.
* New Treatments: Initiation of an antidepressant within 12 weeks before study enrollment or an antipsychotic 6 weeks before study enrollment. No new alternative medications, nutritionals or therapeutic diets within 6 weeks of study enrollment. However, pharmacological interventions may be initiated or added if the child is randomized to the Treatment as Usual arm in Phase II.
* Established Treatment changes: Any change in established psychotropic medication (e.g., antidepressants, anxiolytics) within 8 weeks before study enrollment (6 weeks for antipsychotic). Alternative medications that might have behavioral effects must be stable for 6 weeks prior to the study baseline assessment. Any medications that the child is on must remain stable during treatment unless s/he is randomized to the Treatment as Usual arm in Phase II.
* (a) Current clinically significant suicidality or (b) individuals who have eng…